[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622822":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":11,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":11,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Al-Azhar University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"interventional arm","ACTIVE_COMPARATOR",null,[13],"Drug: Echinacea Extract",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Echinacea Extract","Immulant ® (an extract derived from Echinacea purpurea plant)",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Salah","CONTACT","02+01147491425","majy3000vip@gmail.com",[27],{"facility":28,"status":29,"city":30,"state":11,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"National Nutritional Institute","RECRUITING","Cairo","11731","Egypt","EG",{"type":35,"coordinates":36},"Point",[37,38],31.24967,30.06263,{"lat":38,"lon":37},[41],{"name":28,"role":23,"phone":42,"phoneExt":11,"email":25},"02-01147491425",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Maha Abd Elrhman","Principal Investigator","100622822","phase-2-the-effect-of-echinacea-immulant--in-the-treatment-of-cryptosporidiosis-in-immunocompromised-children-100622822",false,"NCT07388615","The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children","Inclusion Criteria:\n\n* Clinical diagnosis of Cryptosporidiosis Disease\n* Age from 5-12 years\n* Immunocompromised children\n* Not receiving any drugs causing immunosuppression\n\nExclusion Criteria:\n\n* Patients undergoing organ transplantation\n* Patients suffering from autoimmune diseases.\n* Patients suffering from hypersensitivity of this plant extract","ALL","5 Years","12 Years",{"count":57,"type":58},60,"ESTIMATED","INTERVENTIONAL",[61],"PHASE2","This study aims to:\n\n1. To evaluate the effectiveness of Immulant ® addition to standard treatment in reducing clinical symptoms of Cryptosporidiosis in immunocompromised children.\n2. To measure the changes in parasite count in stool samples after treatment with Immulant ®.\n3. To assess the safety and tolerability of Immulant ® in children participating in the study.",[64],"Cryptosporidium Infection","2026-01-28",{"date":67,"type":68},"2026-02-05","ACTUAL",{"date":70,"type":58},"2026-01-18",{"date":72,"type":58},"2026-08",{"name":5,"class":6},1]